Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
for
Advanced Ovarian Carcinoma,
Location: Boston MA, Mineola NY, New York NY, Bethlehem PA,
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 18+
Code: NCT04575935
Phase3, Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Orange City FL, Clermont FL, Detroit MI, Atlanta GA,
Sponsor: Inhibrx Biosciences, Inc
Sex: All
Age: 18+
Code: NCT04198766
Phase1, Phase2, Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
for
Renal Cell Carcinoma (RCC),
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT05176483
Phase1, Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
for
Advanced/Metastatic Solid Tumors, Bladder Cancer,
Location: Boston MA, Newton MA, New Haven CT, Trumbull CT,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07090499
Phase1, Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
for
Cervical Squamous Cell Carcinoma,
Location: New Haven CT, Hackensack NJ, Fairfax VA, Louisville KY,
Sponsor: Alentis Therapeutics AG
Sex: All
Age: 18+
Code: NCT07169734
Phase1, Phase2, Recruiting
Interested in new metastatic urothelial cancer trials?
Get alerts for new trials in your area by subscribing now
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
for
Renal Cell Carcinoma, Urothelial Carcinoma,
Location: Boston MA, Philadelphia PA, Cleveland OH, Ann Arbor MI,
Sponsor: Deciphera Pharmaceuticals, LLC
Sex: All
Age: 18+
Code: NCT06966024
Phase1, Recruiting
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.
Sex: All
Age: 18+
Code: NCT06451497
Phase1, Recruiting
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
for
Bladder Cancer, Metastatic Bladder Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 65+
Code: NCT06138561
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: New York NY, Nashville TN, Houston TX, Dallas TX,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06695845
Phase2, Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract